Generic Name:
lutetium oxodotreotide
Project Status:
Complete
Therapeutic Area:
Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
Manufacturer:
Advanced Accelerator Applications (AAA)
Brand Name:
Lutathera
Project Line:
Reimbursement Review
Project Number:
PC0284-000
Tumour Type:
Gastrointestinal
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive pancreatic neuroendocrine tumours in adults whose disease has progressed after treatment with a somatostatin analogue, unless there is a contraindication or intolerance.
Submission Type:
Reassessment
Fee Schedule:
Schedule A
Tumour Type:
Gastrointestinal
Indications:
For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.